GlassScriptPhysician profile
Jennifer Samaan
NPI 1770183790
$6,491.16
in general payments reported to CMS, 2019-2025
42 companies · $1,139 in 2025
The $1,139 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $971 · 2022: $479 · 2023: $2,010 · 2024: $1,891 · 2025: $1,139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,842 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,842.32 |
| Education | $197.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,531.19 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $825.99 | 2021-2025 | Fasenra, Lokelma, Tezspire |
| Glaxosmithkline, LLC. | $717.71 | 2022-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $573.39 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Genzyme Corporation | $452.78 | 2023-2024 | |
| Lilly USA, LLC | $420.79 | 2021-2024 | Mounjaro, Jardiance, Amyvid |
| Janssen Pharmaceuticals, INC | $410.44 | 2021-2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $197.99 | 2024 | |
| Amgen INC. | $191.45 | 2021-2023 | Repatha, Otezla |
| Jazz Pharmaceuticals INC. | $134.94 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $121.19 | 2023 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $113.93 | 2023-2024 | Xifaxan, Trulance |
| Mallinckrodt Hospital Products INC. | $107.03 | 2021-2024 | Acthar |
| Axsome Therapeutics, INC. | $67.13 | 2023 | Sunosi |
| Merck Sharp & Dohme LLC | $59.30 | 2021-2023 | Pneumovax 23, Vaxneuvance, Gardasil 9 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $49.28 | 2023-2024 | Purified Cortrophin Gel |
| Janssen Biotech, INC. | $44.13 | 2023-2024 | Simponi Aria, Simponi, Stelara |
| Exact Sciences Corporation | $43.36 | 2023-2024 | Cologuard Collection Kit |
| Pfizer INC. | $40.48 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $31.33 | 2023 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $31.13 | 2021-2023 | |
| Amarin Pharma, INC. | $29.64 | 2021 | |
| Dexcom, INC. | $21.25 | 2025 | Dexcom G6 Transmitter |
| Sunovion Pharmaceuticals INC. | $18.76 | 2022 | |
| Redhill Biopharma INC. | $17.29 | 2023 | Talicia |
| Baxter Healthcare | $17.04 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Lundbeck LLC | $16.28 | 2023 | Rexulti |
| Almatica Pharma LLC | $15.30 | 2022 | |
| Paratek Pharmaceuticals, INC. | $15.20 | 2023 | Nuzyra |
| Ardelyx, INC. | $15.18 | 2024 | Ibsrela |
| Urovant Sciences INC | $14.96 | 2022 | |
| Astellas Pharma US INC | $14.87 | 2023 | Myrbetriq |
| Nestle Healthcare Nutrition INC. | $14.06 | 2021 | |
| Inogen, INC. | $13.85 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Endo Pharmaceuticals INC. | $13.77 | 2023 | Nascobal |
| Kowa Pharmaceuticals America, INC. | $13.63 | 2022 | |
| Amphastar Pharmaceuticals, INC. | $13.57 | 2024 | |
| Scilex Pharmaceuticals INC. | $13.28 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.57 | 2021 | |
| Genentech USA, INC. | $12.35 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $12.24 | 2021 | |
| Nevro Corp. | $11.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Samaan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.